Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294649" target="_blank" >RIV/00216208:11110/15:10294649 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10294649
Result on the web
<a href="http://dx.doi.org/10.1007/s10067-014-2816-7" target="_blank" >http://dx.doi.org/10.1007/s10067-014-2816-7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10067-014-2816-7" target="_blank" >10.1007/s10067-014-2816-7</a>
Alternative languages
Result language
angličtina
Original language name
Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
Original language description
Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on immunological parameters. Eighteen RTX-treated AAV patients (M/F 11/7; median age 37.5; 15x PR3-ANCA, 3x MPO-ANCA; 16x relapsing/refractory, 2x first-line therapy) were enrolled. Clinical response, ANCA, total serum IgG levels and cellular immunity parameters were examined. The patients were followed up (FU) for a median of 26 months (range 3-82, 15 for a parts per thousand yen6 months). All patients achieved B cell depletion (lasting 3-24 months). No significant increase was noted in T cell or NK cell subpopulations. At 6 months, partial remission was achieved in 5/15 patients (33 %) and complete in8 (53 %). The median prednisone dose (30..10 mg/d) and ANCA levels (17.2..2.7 IU/mL) decreased (p < 0.01). RTX retreatment was used in nine (8x pre-emptive, 1x relapse). Six patients relapsed (none of the pre-emptively treated). Three pat
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Rheumatology
ISSN
0770-3198
e-ISSN
—
Volume of the periodical
34
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
107-115
UT code for WoS article
000347160600014
EID of the result in the Scopus database
2-s2.0-84925538075